Foramen Ovale, Patent Clinical Trial
Official title:
Investigation of Nickel Sensitization After Percutaneous Implantation of Patent Foramen Ovale Occluder; a RandomizEd Trial.
Percutaneous PFO closure has been established as a first-line therapy for preventing recurrent strokes in selected patients. The devices used for the specific purpose contain and release nickel, which is considered as the most allergen metal in nature. Skin patch tests are considered as gold-standard for documenting nickel allergy. While the allergic contact dermatitis induced by nickel is well described, literature is inadequate on explaining the effect of nickel release on the clinical manifestations of patients implanted with such devices. Our prospective, randomized, blinded trial will try to investigate the above by performing nickel skin patch tests to all patients, 14 days before and 90 days after the implantation. During follow-up, clinical manifestations and transthoracic echocardiographic findings will be evaluated and associated with patch skin tests.
Percutaneous PFO closure has been established as a first-line therapy for preventing recurrent strokes, after embolic stroke of unknown source (ESUS) and a patent foramen ovale. The PFO closure is achieved by the implantation of suitable devices, which occlude the shunt between the two atria and prevent the creation and detachment of thrombi. Until today, there are two devices approved by FDA for the specific purpose; Amplatzer PFO Occluder and Gore Cardioform Septal Occluder. Despite the architectonic differences between these devices, the main material of both is nitinol, an alloy of nickel and titanium. While titanium is an extremely rare allergen, nickel is considered as one of the most common allergens and the most frequent metal allergen in nature, with a prevalence about 20%. The main clinical expression of nickel hypersensitivity is allergic contact dermatitis, but cases with systemic allergic reaction have been described as well. It has been observed that nickel is released by the implanted devices and circulates through bloodstream, having the potential to cause systemic clinical picture. Device syndrome includes signs and symptoms (i.e. palpitations, dyspnea, chest pain, rash, etc.), which are appeared after the device placement and are associated with hypersensitivity reaction. The existing literature is considered as inadequate for explaining the effect of nickel release in the patients implanted with an occluder. Our trial will try to investigate the impact of device placement to nickel skin patch test results and the correlation with the clinical manifestations of patients. Considering that, skin patch tests for nickel and other allergens will be performed in all included patients, 14 days prior and 90 days after the procedure. The patients will be randomized to receive either Amplatzer or Gore device, with parallel assignment and randomization 1:1. During follow-up, clinical manifestations and transthoracic echocardiographic findings will be evaluated and associated with patch skin tests. The time frame of 90 days has been selected, due to the duration of device's endothelization and nickel release. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00196040 -
The Paradigm II Trial: PFX Closure System in Subjects With Cryptogenic Stroke, Transient Ischemic Attack, Migraine or Decompression Illness
|
N/A | |
Recruiting |
NCT01934725 -
Searching for Explanations for Cryptogenic Stroke in the Young: Revealing the Etiology, Triggers, and Outcome
|
||
Enrolling by invitation |
NCT03373929 -
Stitch Closure of PFO and Septal Repair
|
N/A | |
Completed |
NCT02432131 -
Decompression Sickness in Divers With or Without Patent Foramen Ovale
|
||
Recruiting |
NCT04987008 -
Risk of Ischaemic Stroke After Pulmonary Embolism in Patients With and Without Patent Foramen Ovale
|
||
Recruiting |
NCT04881578 -
Atrial Fibrillation Before and After Patent Foramen Ovale Closure Study
|
||
Completed |
NCT02400892 -
Patent Foramen Ovale and the Risk of Postoperative Delirium Following Elective Hip and Knee Arthroplasty Surgeries
|
N/A | |
Recruiting |
NCT01385670 -
InterSEPT: InāTunnel SeptRx European PFO Trial
|
N/A | |
Completed |
NCT02957201 -
The Effect on EPCs by Successful Cardiac Occlusion Device Implantation
|
N/A | |
Completed |
NCT00968032 -
Procedural Success and Safety of the Nit-Occlud® Patent Foramen Ovale (PFO) Closure Device and Its Application System
|
N/A | |
Recruiting |
NCT05558774 -
Long-term Outcomes After Percutaneous Closure of PFO
|
||
Completed |
NCT02127294 -
Effectiveness and Safety of Transcatheter Patent Foramen Ovale Closure for Migraine
|
N/A | |
Recruiting |
NCT01149447 -
Prospective Clinical Follow-up After the Percutaneous Closure of a Patent Foramen Ovale
|
N/A | |
Enrolling by invitation |
NCT05025475 -
Stitch Closure of PFO and Septal Repair (STITCH)
|
N/A | |
Suspended |
NCT04339699 -
NobleStitch EL STITCH Trial is a PFO Comparative Trial
|
N/A | |
Withdrawn |
NCT03232450 -
Patent Foramen Ovale (PFO) Closure at the Time of Endovascular Cardiac Electronic Device Implantation
|
N/A |